RT Journal Article SR Electronic T1 Detection of novel Plasmodium falciparum haplotypes under treatment pressure in pediatric severe malaria JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.08.20.24312296 DO 10.1101/2024.08.20.24312296 A1 Fogang, Balotin A1 Guillochon, Emilie A1 Kamaliddin, Claire A1 Agbota, Gino A1 Ezinmegnon, Sem A1 Alao, Maroufou Jules A1 Deloron, Philippe A1 Bertin, Gwladys A1 Claessens, Antoine YR 2024 UL http://medrxiv.org/content/early/2024/08/20/2024.08.20.24312296.abstract AB Background In Africa, the clearance time for P. falciparum severe malaria varies significantly, likely due to the complexity of P. falciparum infections and the sequestration phenomenon exhibited by this parasite. This study aims to evaluate different methods to study intra-host dynamics of polygenomic infections during parasite clearance under antimalarial treatment. Additionally, it seeks to determine the association between parasite clearance rate following artesunate or quinine treatment and the genetic complexity of P. falciparum in Beninese children with severe malaria.Methods Sixty-five P. falciparum severe malaria individuals diagnosed by microscopy and treated with artesunate or quinine were sampled every 8 hours for 24 hours. Using whole genome sequencing (WGS) data, we estimated the multiplicity of infection (MOI) with three algorithms (Fws, THE REAL McCOIL, and RoH). We then characterized the P. falciparum genetic complexity in WGS-identified polyclonal infections using amplicon sequencing (AmpSeq) on DNA extracted from plasma and from the red blood cells pellet.Results AmpSeq demonstrated greater sensitivity in detecting multiple genomes within isolates compared to WGS methods. The MOI from AmpSeq was significantly higher in RBC pellets compared to plasma (2.4 vs 1.8 distinct microhaplotypes per isolate). However, at parasitaemia over 1000 parasites/uL, the same MOI was detected in both plasma and pellet samples in 85.4% of the isolates. We observed a high variability in parasite clearance rate among participants, but it was not associated with parasite MOI at diagnostic. Interestingly, in 60.9% of participants, previously undetected microhaplotypes appeared in circulation 16 hours after treatment initiation.Conclusion These findings demonstrate that combining different haplotyping techniques effectively determines parasite genetic complexity. Additionally, plasma can be effectively used for parasite genotyping at sufficient parasitaemia levels. The parasite clearance rate of severe malaria is independent of parasite MOI. However, genotyping a single blood sample upon hospital admission does not capture the full spectrum of parasite genotypes present in the infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from the French National Research Agency (18‐CE15‐0009‐01), the ATIP-Avenir programme and by Institut Merieux. The SPF‐Post doc en France programme of the Fondation pour la Recherche Médicale funded the author Balotin Fogang (SPF202209015889).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of "Institut des Sciences Biomedicales Appliquees Benin" (clearance number 90, 06/06/2016 and clearance number 38, 16/05/2014) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript or are available online at the European Nucleotide Archive (ENA) under the study accession number PRJEB2136 and on Zenodo at https://zenodo.org/records/13224728. https://www.ebi.ac.uk/ena/browser/view/PRJEB2136 https://zenodo.org/records/13224728